The administration’s emerging “most favored nation” strategy would peg what Medicare pays for certain drugs to the far lower prices charged in other wealthy countries, shattering the long‑standing norm that Americans pay more than anyone else. It could arrive by executive order, fast-tracking a process that bypasses a gridlocked Congress but all but guarantees immediate legal warfare and fierce lobbying from pharmaceutical giants.

Yet the political and moral pressure is mounting. Previous attempts collapsed under lawsuits and regulatory missteps, but the underlying crisis has only deepened: seniors rationing insulin, cancer patients skipping doses, families drowning in bills for medicines developed with public support. This time, officials appear determined to test how far executive power can stretch to force a reckoning. Whether the plan survives the courts or not, it signals a turning point: the era of unquestioned drug pricing may finally be nearing its end.